Peptide Half-Life Explained: Why It Matters

Half-life is the time it takes for the concentration of a substance in the body to decrease by half. It's one of the most fundamental pharmacokinetic parameters and directly determines how frequently a compound needs to be administered to maintain effective levels.

A simple example: If you administer 100mcg of a peptide with a 2-hour half-life, after 2 hours approximately 50mcg remains active. After 4 hours (two half-lives), approximately 25mcg remains. After 6 hours, approximately 12.5mcg. The peptide is generally considered eliminated after 4-5 half-lives.

Why half-life matters for peptides: - Dosing frequency — Short half-life peptides require more frequent administration to maintain therapeutic levels. Long half-life peptides can be dosed less frequently. - Peak vs sustained levels — Short half-life peptides create sharp peaks followed by rapid decline. Long half-life peptides maintain more stable, sustained concentrations. - Research design — Understanding half-life is essential for designing research protocols with appropriate timing and frequency. - Physiological mimicry — For some applications (like GH secretagogues), matching the peptide's activity pattern to natural biological rhythms may be important.

Factors affecting half-life: - Molecular size (larger peptides tend to have longer half-lives) - Structural modifications (PEGylation, fatty acid conjugation, DAC) - Route of administration (subcutaneous vs intravenous vs oral) - Individual metabolic variation - Protein binding in the bloodstream

Understanding relative half-lives helps contextualise dosing protocols and expected activity patterns:

Very short half-life (minutes): - Natural GLP-1 — 2-3 minutes (this is why synthetic analogues were developed) - Natural GHRH — 7-10 minutes - Mod GRF 1-29 (CJC-1295 no DAC) — approximately 30 minutes - Ipamorelin — approximately 2 hours - GHRP-6 — approximately 2 hours - Sermorelin — approximately 10-20 minutes

Medium half-life (hours): - BPC-157 — estimated 4-6 hours (limited pharmacokinetic data available) - TB-500 — approximately 6-8 hours in some estimates (Thymosin Beta-4 data varies) - GHK-Cu — relatively short when injected; topical persistence depends on formulation

Long half-life (days): - CJC-1295 with DAC — approximately 6-8 days (the DAC modification dramatically extends duration) - Semaglutide — approximately 7 days (fatty acid side chain enables weekly dosing) - Tirzepatide — approximately 5 days

Very long half-life: - PEGylated peptides — Can extend half-life to weeks depending on PEG size and attachment

Important note: Many research peptide half-lives are estimated from animal data or inferred from structural properties. Precise human pharmacokinetic data is only available for pharmaceutical peptides that have undergone formal clinical trials.

Native peptides are rapidly broken down by enzymes (peptidases) in the blood and tissues. Several engineering strategies have been developed to extend peptide half-life:

Fatty acid conjugation (lipidation) Attaching a fatty acid chain to the peptide allows it to bind reversibly to albumin — a large, abundant protein in the blood. Since albumin has a half-life of approximately 19 days, the bound peptide is protected from enzymatic degradation. This is the strategy used by semaglutide (C-18 fatty diacid chain) and liraglutide (C-16 fatty acid chain).

Drug Affinity Complex (DAC) The DAC modification used in CJC-1295 allows the peptide to bind covalently to albumin after injection. This essentially "hitches a ride" on albumin, extending the half-life from 30 minutes (without DAC) to approximately 6-8 days (with DAC). The trade-off is that the sustained release produces a different biological effect than the pulsatile release of the non-DAC version.

PEGylation Attaching polyethylene glycol (PEG) chains to peptides increases their molecular size, reducing renal clearance and enzymatic degradation. PEGylation is widely used in pharmaceutical development but can reduce receptor binding affinity depending on where the PEG chain is attached.

D-amino acid substitution Replacing natural L-amino acids with their mirror-image D-amino acids at specific positions makes the peptide resistant to enzymatic cleavage. D-amino acid-containing peptides are not recognised by most peptidases, significantly extending their stability.

Cyclisation Connecting the ends of a linear peptide to form a circular structure increases resistance to exopeptidases (enzymes that attack peptide ends). Cyclic peptides are an active area of pharmaceutical development.

Understanding half-life has direct practical implications for peptide research:

Dosing frequency alignment: - Semaglutide (7-day half-life) → once-weekly administration - CJC-1295 with DAC (6-8 day half-life) → once or twice weekly - BPC-157 (4-6 hour estimated half-life) → typically 1-2x daily in research protocols - Ipamorelin (2 hour half-life) → typically 2-3x daily - Mod GRF 1-29 (30 min half-life) → typically 2-3x daily, often timed with Ipamorelin

Steady-state considerations: It takes approximately 4-5 half-lives to reach steady state — the point where the amount of peptide being administered equals the amount being eliminated. For semaglutide, this means steady state is reached after 4-5 weeks of weekly dosing. For BPC-157, steady state would be reached within 1-2 days of regular dosing.

Timing relative to biological rhythms: For GH secretagogues, timing administration to coincide with natural GH troughs (typically morning, post-exercise, or before sleep) may maximise the pulsatile release. Administering during natural GH peaks may not add significant benefit because the pituitary is already active.

Washout periods: The time needed for a peptide to be fully eliminated after discontinuation is approximately 4-5 half-lives. Semaglutide requires 4-5 weeks for full clearance, while BPC-157 would clear within approximately 24-30 hours. This is relevant for researchers planning sequential protocols or transitioning between compounds.

The key takeaway: Half-life isn't just an academic concept — it directly determines the practical design of research protocols, from dosing frequency to timing to washout periods. Matching administration schedules to a peptide's pharmacokinetic profile is essential for consistent, meaningful research outcomes.